Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

As Official Media Partner, VJHemOnc covered the 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL), held in Cambridge, MA, from September 6–8, 2019. This brought together world-leading researchers in lymphoma to discuss the latest data in the field.

Highlighted at the meeting this year were novel treatments in CAR T-cell therapy and the genetics underlying the prognostic features of NHL.

iwNHL 2019

06–08 September 2019 | Cambridge, Massachusetts

iwNHL 2019

06–08 September 2019 | Cambridge, Massachusetts

As Official Media Partner, VJHemOnc covered the 17th International Workshop on Non-Hodgkin Lymphoma (iwNHL), held in Cambridge, MA, from September 6–8, 2019. This brought together world-leading researchers in lymphoma to discuss the latest data in the field.

Highlighted at the meeting this year were novel treatments in CAR T-cell therapy and the genetics underlying the prognostic features of NHL.

Developing mantle cell lymphoma treatment for further success 1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla • 11 Nov 2019
Update on selinexor for myeloma and large cell lymphomas 2:02
Update on selinexor for myeloma and large cell lymphomas
John Kuruvilla • 11 Nov 2019
Possibilities for the use of pembrolizumab in lymphoma treatment 1:36
Possibilities for the use of pembrolizumab in lymphoma treatment
John Kuruvilla • 11 Nov 2019
CAR-T vs bispecific antibodies for lymphoma 12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al. • 17 Sep 2019
Will knowledge of the molecular pathology of lymphoma improve clinical trials? 11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al. • 17 Sep 2019
The need for academic and pharmaceutical collaboration in drug development 9:19
The need for academic and pharmaceutical collaboration in drug development
Jay Bradner et al. • 17 Sep 2019
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization 10:20
The lymphoma tumor microenvironment: therapeutic targeting, genetics, drug optimization
Laura Pasqualucci et al. • 17 Sep 2019
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1 12:31
T-cell lymphomas: murine models, in-situ treatments & screening for HTLV1
David Weinstock et al. • 16 Sep 2019
CAR-T for lymphoma: new targets, real world data & resistance 10:57
CAR-T for lymphoma: new targets, real world data & resistance
Barbara Savoldo et al. • 13 Sep 2019
Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think? 15:11
Genetic basis of immune evasion in lymphoid malignancies: more heterogenetity than we think?
John Gribben et al. • 6 Sep 2019

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals